Cisplatine Induced Hearing Loss clinical trials

Explore recruiting cisplatine induced hearing loss clinical trials.

Also recruiting in Europe

Cisplatine Induced Hearing Loss trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase IIa, Multicenter, Randomized, Controlled, Open label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity induced by Cisplatin in Adult Subjects with a Neoplastic Disease

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Cisplatine Induced Hearing Loss trials by city

Cisplatine Induced Hearing Loss in Toronto Cisplatine Induced Hearing Loss in Vancouver Cisplatine Induced Hearing Loss in Montreal Cisplatine Induced Hearing Loss in Calgary Cisplatine Induced Hearing Loss in Edmonton Cisplatine Induced Hearing Loss in Ottawa Cisplatine Induced Hearing Loss in Winnipeg Cisplatine Induced Hearing Loss in Quebec City Cisplatine Induced Hearing Loss in Hamilton Cisplatine Induced Hearing Loss in Kitchener Cisplatine Induced Hearing Loss in London Cisplatine Induced Hearing Loss in Halifax Cisplatine Induced Hearing Loss in New York Cisplatine Induced Hearing Loss in Los Angeles Cisplatine Induced Hearing Loss in Chicago Cisplatine Induced Hearing Loss in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease